Advice

following an abbreviated submission:

rufinamide (Inovelon®) is accepted for restricted use within NHSScotland.

Indication under review: as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to <4 years.

SMC restriction: restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs.

Rufinamide (Inovelon®) has previously been accepted for restricted use in adults and children aged ≥4 years. The licence has been extended to include children aged 1 year to <4 years.

Download detailed advice362KB (PDF)

Download

Medicine details

Medicine name:
rufinamide (Inovelon)
SMC ID:
SMC2146
Indication:
as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years of age and older
Pharmaceutical company
Eisai Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published:
08 April 2019